Kiniksa - KNSA Total Company Value-to-Revenue Ratio

Kiniksa (KNSA) - corporate logo

The humanitarian status of Kiniksa Pharmaceuticals (KNSA) developments minimizes geopolitical risks, supporting a positive trend in the Enterprise Value to revenue ratio. However, reliance on external CMO/CROs and potential chemical supply disruptions due to trade conflicts create certain volatility. Consequently, the indicator reaches 7176.12, confirming the current market valuation of the business relative to its turnover.

KNSA: Kiniksa Pharmaceuticals EV/Sales Multiple 11/23/2025 - 11/20/2026

KNSA (Kiniksa Corp): analytical breakdowns and indicator data

- cash and cash flow indicators:
Fundamental company valuation:KNSA - Kiniksa
Mass-produced product of Kiniksa Pharmaceuticals Ltd

The market assesses the potential of Kiniksa Pharmaceuticals (KNSA) through the lens of its portfolio diversification across rare immune and cardiovascular drugs. Analyzing the EV/Sales chart, an investor can view the business value relative to revenue regardless of debt load, which eliminates financial noise and determines the true fundamental value of the assets, confirming the company's long-term sustainability.

Direct competitors

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|GRFS: Enterprise Value to Sales Volume|Adaptive Biotechnologies - Company Value to Revenue|CLDX: Company Value to Revenue Ratio|Aurinia Corp - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BioCryst Corp|VERA: EV/Sales Multiple|dianthustx.com (DNTH) - EV/Sales Multiple|PHVS (Pharvaris NV) - EV/Sales Multiple|ABCL: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tourmaline Bio, Inc. (TRML)|PGEN (Intrexon) - Business Value to Revenue|EV/Sales Multiple PHAR (Pharming Corp)|nektar.com (NKTR) - Enterprise Value-to-Revenue Multiple|UPB - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ZBIO (Zenas Biopharma)|IMNM: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gossamer Bio, Inc. (GOSS)|Enterprise Value-to-Revenue Ratio KalVista Pharmaceuticals|Septerna Inc (SEPN) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PVLA|SVRA (Savara) - Business Value to Revenue|Rigel Pharma - Company Value to Revenue|Total Company Value-to-Revenue Ratio AnaptysBio Corp (ANAB)|ATXS: Company Value to Revenue|Business Value to Revenue ENGN (enGene Holdings Inc.)|RAPT Therapeutics Inc. (RAPT) - Enterprise Value-to-Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - EV/Sales Multiple|ACRS (Aclaris Therapeutics, Inc) - EV/Sales Multiple|Kyverna (KYTX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple TLSA|Company Value to Revenue Cabaletta Bio, Inc. CABA|Ventyx Biosciences - Company Value to Revenue|THTX: Company Value to Revenue Ratio|AVTX - Enterprise Value-to-Revenue Ratio|ELDN: Enterprise Value-to-Revenue Ratio|Agenus Inc. (AGEN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Climb Bio Inc|ZURA (Zura Bio Ltd) - EV/Sales Multiple|EV/Sales Multiple aTyr Pharma Inc|EV/Sales Multiple ADAG|Total Company Value-to-Revenue Ratio ImageneBio|EV/Sales Multiple STTK (Shattuck Labs Inc)|EV/Sales Multiple Equillium, Inc. EQ|CNTB - Enterprise Value-to-Revenue Ratio|Immunic Therapeutics (IMUX) - Company Value to Revenue|ATRA: EV/Sales Multiple|InflaRx GmbH (IFRX) - EV/Sales Multiple|XFOR (x4pharma.com) - EV/Sales Multiple|EV/Sales Multiple Adicet Bio|Enterprise Value-to-Revenue Ratio Celularity Inc (CELU)|Company Value to Revenue INmune Bio Corp INMB|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD